Promoting Sleep and Healthy Aging Research Study (PRO-SHARE)

Inclusion Criteria:

- Older adults >= 60 year of age

- Evidence of self-reported sleep disturbance as indexed by PSQI scores >5.

Exclusion Criteria:

Psychiatric Disorders.

1. current major depressive disorder or other DSM-IV psychiatric disorder (e.g. substance
dependence) with the exception of a anxiety disorder;

2. presence of psychotic symptoms

3. acute suicidal or violent behavior or history of suicide attempt within the last year;

Sleep Disorders.

4. current or lifetime history of sleep disorder (sleep apnea, nocturnal myoclonus,
phase-shift disorder) as identified by SCID-IV and the Duke Structured Interview for
Sleep Disorders (DSISD); persons with co-morbid insomnia will be included

Medical conditions.

5. severe or acute medical illness (e.g., major surgery, metastatic cancer, stroke, or
myocardial infarction) six months prior to study entry presence of co-morbid medical
conditions; 5) neurological diseases (e.g., Parkinson's diseases, multiple sclerosis;
neurodegenerative dementia,);

6. severe pain disorders requiring daily pain management;

7. presence of co-morbid inflammatory disorders such as rheumatoid arthritis and other
autoimmune disorders that would confound the assessment of sleep as well as
inflammatory markers;

8. presence of uncontrolled medical condition that is deemed by the investigators to
interfere with the proposed study procedures, or put the study participant at undue
risk (e.g., an active heart failure categorized as Class III or greater according to
New York Heart Association criteria; symptomatic cardiac arrhythmias; symptomatic,
hemodynamically significant mitral or aortic valvular disease);

9. presence of chronic infections, which may elevate proinflammatory cytokines. While we
will not exclude this individuals only behavioral outcomes will be measured on these
subjects. No analysis of blood will be performed. (If a history of an acute infectious
illness is identified within two weeks of a scheduled blood sampling, the session will
be rescheduled to occur outside this two week period);

Medication and substance use.

10. use of hormone containing medications including steroids;

11. immune modifying drugs that target specific immune responses agents such as TNF
antagonists;

12. daily use of analgesics such as opioids. We will include those taking psychotropic
medications (except for anti-psychotic medications or who have have been treated with
a depot-neuroleptic within 6 months prior to study entry) In regards to psychotropic
medication use, we will quantify past, current, and ongoing use of psychotropic
medications (e.g., selective serotonin reuptake inhibitors, other antidepressants,
anxiolytics, hypnotics, sedatives) and assess the effects of these medications on
primary outcomes during the intervention, and follow-up period.